

# Quinox<sup>®</sup>

*Ciprofloxacin Film Coated Tablet*

## DESCRIPTION

**Quinox<sup>®</sup>** is the preparation of Ciprofloxacin Hydrochloride, a synthetic broad-spectrum antimicrobial agent for oral administration. The bactericidal action of ciprofloxacin results from the inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.

## INDICATIONS

**Quinox<sup>®</sup>** is indicated for the treatment of infections caused by susceptible organisms e.g. infectious diarrhoea, complicated intra abdominal infections, typhoid fever, bone and joint infections, skin and skin structure infections, lower respiratory infections, urinary tract infections, urethral and cervical gonococcal infections, chronic bacterial prostatitis and acute sinusitis.

## DOSAGE AND ADMINISTRATIONS

The dosage of Ciprofloxacin is determined by the severity and type of infection, the sensitivity of the causative organism(s) and the age, weight and renal function of the patient.

**Adults:** Recommended dose is 250 - 750 mg twice daily.

**Children (above 1 year):** The dosage should be 10 - 20 mg/kg/day depending upon the severity of infection, administered in two divided doses.

## SIDE-EFFECTS

The adverse reactions which have occasionally been observed are nausea, anorexia, constipation, diarrhoea, flatulence, thirst, vomiting, abdominal pain, depersonalization, dizziness, hypertonia, incoordination, somnolence, maculopapular rash, pruritus, rashes, skin disorder, vesiculobullous rash, taste perversion, dysmenorrhoea, vaginal candidiasis, vaginitis.

## PRECAUTIONS

Ciprofloxacin should be used with caution in patients with a history of convulsive disorders. Crystalluria related to the use of ciprofloxacin has been observed rarely. Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints and/or surrounding tissues in juveniles.

## CONTRAINDICATIONS

Ciprofloxacin is contraindicated in patients who are hypersensitive to ciprofloxacin or any member of the quinolone class of antimicrobial agents.

## USE IN PREGNANCY AND LACTATION

There is no adequate and well-controlled study in pregnant women. Ciprofloxacin is excreted in human breast milk. Safety of Ciprofloxacin in pregnant and lactating women is not established.

## DRUG INTERACTION

Concurrent administration of Ciprofloxacin with theophylline and caffeine may increase the adverse effects of theophylline and caffeine. Quinolones, including ciprofloxacin, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.

## PHARMACEUTICAL PRECAUTIONS

Do not store above 30 °C. Keep away from light and wet place. Keep out of reach of children.

## PACKAGING

**Quinox<sup>®</sup> 250 tablet:** Box containing 3 strips of 10 tablets each. Each film coated tablet contains Ciprofloxacin Hydrochloride USP equivalent to 250 mg Ciprofloxacin.

**Quinox<sup>®</sup> 500 tablet:** Box containing 2/4 strips of 10 tablets each. Each film coated tablet contains Ciprofloxacin Hydrochloride USP equivalent to 500 mg Ciprofloxacin.

**Quinox<sup>®</sup> 750 tablet:** Box containing 1 strip of 10 tablets. Each film coated tablet contains Ciprofloxacin Hydrochloride USP equivalent to 750 mg Ciprofloxacin.

**SK•F**

Manufactured by  
**ESKAYEF PHARMACEUTICALS LTD.**

MIRPUR, DHAKA, BANGLADESH

© REGD. TRADEMARK

M/PM00394 V04